How to select a nanosimilar

Alain Astier¹, Amy Barton Pai², Marco Bissig³, Daan JA Crommelin⁴, Beat Flühmann⁵, Jean-Daniel Hecq⁶, Josefien Knoeff⁵,⁷, Hans-Peter Lipp⁸, Alberto Morell-Baladaron⁹ and Stefan Mühlebach⁵,¹⁰

¹Department of Pharmacy, Henri Mondor University Hospitals, Créteil, France.
²Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
³Hospital Pharmacy, Ospedale Regionale di Lugano, Lugano, Switzerland.
⁴Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.
⁵Vifor Pharma Ltd., Glattbrugg, Switzerland.
⁶Hospital Pharmacy, University Hospital of Mont-Godinne, Yvoir, Belgium.
⁷Faculty of Sciences, Vrije Universiteit Amsterdam, the Netherlands.
⁸Hospital Pharmacy, Universitätsklinikum Tübingen, Germany.
⁹Hospital Pharmacy, La Princesa Hospital, Madrid, Spain.
¹⁰Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

Abstract

Nanomedicines in the class of nonbiological complex drugs (NBCDs) are becoming increasingly available. Up to 23 nanomedicines have been approved, and approximately 50 are in clinical development. Meanwhile, the first nanosimilars have entered the market through the generic approval pathway, but clinical differences have been observed. Many healthcare professionals may be unaware of this issue and must be informed of these clinically relevant variances. This article provides a tool for rational decision making for the inclusion of nanomedicines into the hospital formulary, including defined criteria for evaluation of substitutability or interchangeability. The tool was generated by conducting a roundtable with an international panel of experts and follows the same thought process that was developed and published earlier for the selection of biologicals/biosimilars. In addition to the existing criteria for biosimilars, a set of seven criteria was identified that specifically apply to nanosimilars. These include (1) particle size and size distribution, (2) particle surface characteristics, (3) fraction of unoccupied bioactive moiety, (4) stability on storage, (5) bioactive moiety uptake and (6) distribution, and (7) stability for ready-to-use preparation. Pharmacists should utilize their pharmaceutical expertise to use the appropriate criteria to evaluate the comparability of the drug to decide on interchangeability or substitutability.

Contact: beat.fluehmann@viforpharma.com